Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 2007

Conditions
HIV Infections
Interventions
DRUG

Lopinavir/Ritonavir

Trial Locations (17)

10457

Bronx-Lebanon Hosp. IMPAACT CRS, The Bronx

21201

Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore

21287

Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore

32209

Univ. of Florida Jacksonville NICHD CRS, Jacksonville

381052794

St. Jude/UTHSC CRS, Memphis

606143394

Chicago Children's CRS, Chicago

94609-1809

Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab., Oakland

94143-0105

UCSF Pediatric AIDS CRS, San Francisco

80218-1088

Univ. of Colorado Denver NICHD CRS, Aurora

Unknown

Children's National Med. Ctr. Washington DC NICHD CRS, Washington D.C.

USF - Tampa NICHD CRS, Tampa

St. Christopher's Hosp. for Children, Philadelphia

SOM Federal University Minas Gerais Brazil NICHD CRS, Minas Gerais

Univ. of Sao Paulo Brazil NICHD CRS, São Paulo

San Juan City Hosp. PR NICHD CRS, San Juan

021155724

Children's Hosp. of Boston NICHD CRS, Boston

01199

Baystate Health, Baystate Med. Ctr., Springfield

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH